(Q34043643)

1 July 2019

review article

1 reference

title

Adoptive cell transfer as personalized immunotherapy for human cancer (English)

1 reference

1 July 2019

1 reference

Nicholas P Restifo

2

0 references

Steven Rosenberg

series ordinal

1

object named as

Steven A Rosenberg

1 reference

1 July 2019

language of work or name

English

0 references

publication date

1 April 2015

1 reference

1 July 2019

number of pages

7

1 reference

inferred from page(s)

published in

Science

1 reference

1 July 2019

volume

348

1 reference

1 July 2019

issue

6230

1 reference

1 July 2019

page(s)

62-68

1 reference

1 July 2019

Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Successful treatment of melanoma brain metastases with adoptive cell therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Adoptive immunotherapy for cancer: harnessing the T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

A human memory T cell subset with stem cell-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Mutational heterogeneity in cancer and the search for new cancer-associated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Therapeutic cancer vaccines: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Neoantigens in cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Adoptive immunotherapy for cancer: building on success

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Disparate individual fates compose robust CD8+ T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Heterogeneous differentiation patterns of individual CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Th17 cells are long lived and retain a stem cell-like molecular signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Directed evolution of human T-cell receptors with picomolar affinities by phage display.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

CD19CAR T cells: From humble beginnings to cancer immunotherapy's poster child

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

The basic principles of chimeric antigen receptor design

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Current concepts in the diagnosis and management of cytokine release syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Genome editing. The new frontier of genome engineering with CRISPR-Cas9

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Chimeric antigen receptor T cells for sustained remissions in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA4967

Immunotherapy through TCR gene transfer

21 January 2018

1 reference

12 December 2020

TREATMENT OF PRIMARY FIBROSARCOMA IN THE RAT WITH IMMUNE LYMPHOCYTES

1 reference

12 December 2020

Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.

1 reference

12 December 2020

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

12 December 2020

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

12 December 2020

Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice.

1 reference

12 December 2020

The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma

1 reference

12 December 2020

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

12 December 2020

Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells

1 reference

12 December 2020

Identifiers

DOI

10.1126/SCIENCE.AAA4967

1 reference

1 July 2019

PMC publication ID

6295668

1 reference

1 July 2019

PubMed publication ID

25838374

1 reference

1 July 2019